Bc. Knight et al., ALLOGENEIC MURINE MELANOMA CELL VACCINE - A MODEL FOR THE DEVELOPMENTOF HUMAN ALLOGENEIC CANCER VACCINE, Melanoma research, 6(4), 1996, pp. 299-306
In an attempt to induce an immune response against tumour antigens, se
veral groups are transfecting cytokine and other genes into autologous
tumour cells which are given to the patient as a vaccine. This proces
s is labour-intensive, time-consuming and expensive. Allogeneic cells
would offer a more convenient vehicle for the delivery of cytokines an
d other molecules. However, current dogma suggests that MHC-matched ce
lls are a prerequisite for an effective immune response. Using murine
melanoma models we compared allogeneic and autologous vaccination and
showed that the survival of C56BL/6 mice (H-2(b)) was prolonged with s
ome degree of protection achieved against an autologous B16-F10 (H-2(b
)) cell challenge when the mice were vaccinated with allogeneic K1735-
M2 (H-2(k)) cells but not when immunized with autologous B16-F10 cells
, Both vaccination with live and irradiated allogeneic cells induced a
n anti-tumour effect using only one immunization and no boost or adjuv
ant, Protection was not observed after vaccination with another melano
ma (S91; H-2(d)) or with a carcinoma (A9HT; H-2(k)). Allogeneic vaccin
ation promoted a cytotoxic cellular response against both the allogene
ic and the syngeneic melanomas, This allogeneic vaccination model will
be useful for studying the underlying mechanisms of protection, in bo
th pre- and post-challenge settings, as well as for developing whole c
ell vaccination systems using genetically modified allogeneic tumour c
ells.